US 12,213,989 B2
Use of maribavir in treatment regimens
Heng Song, Lexington, MA (US); Kefeng Sun, Needham, MA (US); Matthew Crouthamel, Chelmsford, MA (US); Grace Chen, Libertyville, IL (US); Andy Z. X. Zhu, Winchester, MA (US); Ingrid Nicolle Michon, Voorschoten (NL); Howard James Burt, Sheffield (GB); Zoe Elizabeth Barter, Nottingham (GB); and Sibylle Neuhoff, Sheffield (GB)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Apr. 25, 2024, as Appl. No. 18/646,035.
Application 18/646,035 is a continuation of application No. 18/400,304, filed on Dec. 29, 2023, abandoned.
Application 18/400,304 is a continuation of application No. PCT/US2022/050341, filed on Nov. 18, 2022.
Claims priority of provisional application 63/281,206, filed on Nov. 19, 2021.
Prior Publication US 2024/0285663 A1, Aug. 29, 2024
Int. Cl. A61K 31/7056 (2006.01); A61K 31/4166 (2006.01); A61K 31/513 (2006.01); A61K 31/55 (2006.01)
CPC A61K 31/7056 (2013.01) [A61K 31/4166 (2013.01); A61K 31/513 (2013.01); A61K 31/55 (2013.01)] 7 Claims
 
1. A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising
administering maribavir in an amount of 1200 mg orally twice daily, wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,
wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant.